Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead 
Welcome,         Profile    Billing    Logout  
 50 Diseases   11 Trials   11 Trials   833 News 


«123456789101112»
  • ||||||||||  Lexiscan (regadenoson) / Astellas, GE Healthcare
    [VIRTUAL] PROGNOSTIC VALUE OF NEAR NORMAL REGADENOSON SPECT MYOCARDIAL PERFUSION IMAGING (Non Invasive Imaging Moderated Poster Theater_eAbstract Virtual Hall) -  Dec 22, 2019 - Abstract #ACC2020ACC_3808;    
    Near normal MPI or borderline ischemia is associated with increased risk of “soft events” of CD/MI/CR and CD/MI/LCR, but not “hard events” of CD/MI. Nonetheless, these minimal abnormalities should not be dismissed.
  • ||||||||||  Lexiscan (regadenoson) / Astellas, GE Healthcare
    [VIRTUAL] THE PROGNOSTIC VALUE OF REGADENOSON STRESS MYOCARDIAL PERFUSION IMAGING: THE LARGEST COHORT TO DATE (Non Invasive Imaging Moderated Poster Theater_eAbstract Virtual Hall) -  Dec 22, 2019 - Abstract #ACC2020ACC_3807;    
    Nonetheless, these minimal abnormalities should not be dismissed. In the largest cohort to date, we showed that the presence and severity of MPI abnormalities or myocardial ischemia on regadenoson SPECT MPI is associated with independent and incremental increase in MACE risk.
  • ||||||||||  Lexiscan (regadenoson) / Astellas, GE Healthcare
    [VIRTUAL] ELEVATED TROPONIN WITH NO MYOCARDIAL INJURY: HETEROPHILE ANTIBODY CROSS-REACTION (FIT Clinical Decision Making Moderated Poster Theater 2_eAbstract Virtual Hall) -  Dec 22, 2019 - Abstract #ACC2020ACC_3436;    
    Often times, modern practice disproportionately emphasizes laboratory troponin I assay in the evaluation of patients with chest pain. This case highlights the importance of integrating patient’s presentation, medical history and a high suspicion for false positive laboratory results to guide management.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion, Enrollment change, Trial completion date, Trial primary completion date:  Microvascular Dysfunction in Nonischemic Cardiomyopathy: Insights From CMR Assessment of Coronary Flow Reserve (clinicaltrials.gov) -  Dec 12, 2019   
    P4,  N=31, Completed, 
    This case highlights the importance of integrating patient’s presentation, medical history and a high suspicion for false positive laboratory results to guide management. Recruiting --> Completed | N=75 --> 31 | Trial completion date: Sep 2019 --> Mar 2019 | Trial primary completion date: Sep 2019 --> Mar 2019
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Journal:  Review of cardiovascular imaging in the Journal of Nuclear Cardiology in 2017. Part 2 of 2: Myocardial perfusion imaging. (Pubmed Central) -  Nov 28, 2019   
    In the first article of this 2-part series, we focused on publications dealing with positron emission tomography, computed tomography, and magnetic resonance. This review will place emphasis on myocardial perfusion imaging using single-photon emission computed tomography summarizing advances in the field including prognosis, safety and tolerability, the impact of imaging on management, and the use of novel imaging protocols.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Enrollment closed, Trial completion date, Trial primary completion date:  Stress Test in Detecting Heart Damage in Premenopausal Women With Stage I-III Breast Cancer (clinicaltrials.gov) -  Nov 27, 2019   
    P=N/A,  N=25, Active, not recruiting, 
    This review will place emphasis on myocardial perfusion imaging using single-photon emission computed tomography summarizing advances in the field including prognosis, safety and tolerability, the impact of imaging on management, and the use of novel imaging protocols. Recruiting --> Active, not recruiting | Trial completion date: Dec 2020 --> Mar 2020 | Trial primary completion date: Dec 2019 --> Mar 2020
  • ||||||||||  Lexiscan (regadenoson) / Astellas
    Preclinical, Journal:  Influence of hemodialysis on regadenoson clearance in an in vitro hemodialysis model. (Pubmed Central) -  Nov 11, 2019   
    Hemodialysis enhances the clearance of regadenoson independent of hemodialyzer permeability and blood/dialysate flow rate. This clearance is modest relative to total body clearance and is unlikely to produce a clinically significant outcome.
  • ||||||||||  Lexiscan (regadenoson) / Astellas
    Journal:  Regadenoson use in chronic kidney disease and end-stage renal disease: A focused review. (Pubmed Central) -  Nov 11, 2019   
    Based on accumulating data since its initial approval, the FDA has recently outlined the use of regadenoson in patients with ESRD in a label update on January 17, 2017. In this review, we discuss the evidence leading to the recent label update, focusing on the pharmacokinetics of regadenoson in patients with impaired kidney function, the safety and tolerability of regadenoson in patients with chronic kidney disease and ESRD, and the prognostic value of regadenoson stress MPI in this patient population.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion:  Assessment of Global Myocardial Perfusion Reserve Using Coronary Sinus Flow Measurements (clinicaltrials.gov) -  Oct 26, 2019   
    P=N/A,  N=183, Completed, 
    Herein, we summarize literature to date on the combination of vasodilator and exercise stress testing in light of the recently published Exercise to Regadenoson in Recovery Trial (EXERRT). Recruiting --> Completed
  • ||||||||||  Lexiscan (regadenoson) / Astellas
    A CASE OF STEMI FOLLOWING NUCLEAR STRESS TEST: NOT JUST STEAL PHENOMENON (Ernest N. Morial Convention Center - Exhibit Hall - Poster Area 4) -  Sep 25, 2019 - Abstract #CHEST2019CHEST_1353;    
    In our case, patient had a clearly defined ST segment elevation indicative of ongoing ischemia which could be secondary to possible coronary steal syndrome. There should be more research into the importance of ST segment elevation during the regadenoson stress testing along with other variables to provide more accurate diagnostic and prognostic predictions.
  • ||||||||||  Lexiscan (regadenoson) / Astellas
    Dynamic Solid State SPECT Evaluation of Myocardial Blood Flow in Hemodialysis Patients (Zone 4, Science and Technology Hall) -  Sep 20, 2019 - Abstract #AHA2019AHA_8378;    
    Tracer injection was performed 50s after regadenoson stress... Myocardial flow quantification with dynamic SPECT is feasible in the clinical setting and may provide physiological insights beyond conventional MPI.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion, Trial completion date:  Utility of Regadenoson Low-dose Dynamic Computed Tomography for Myocardial Perfusion Assesment (ULYSSES Study). (clinicaltrials.gov) -  Sep 17, 2019   
    P=N/A,  N=60, Completed, 
    Myocardial flow quantification with dynamic SPECT is feasible in the clinical setting and may provide physiological insights beyond conventional MPI. Recruiting --> Completed | Trial completion date: Nov 2019 --> Jul 2019
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion, Enrollment change:  Reducing Radioisotope Dose: the Half-Dose CZT Study (clinicaltrials.gov) -  Sep 6, 2019   
    P=N/A,  N=74, Completed, 
    Therefore, careful observation and scrutiny of all ECG changes, especially new, isolated T-wave inversion in multiple ECG leads during regadenoson MPI is advisable to identify potential obstructive CAD despite normal MPI findings. Recruiting --> Completed | N=50 --> 74
  • ||||||||||  Lexiscan (regadenoson) / Astellas
    Arm Exercise ECG is Equivalent to Regadenoson Stress for Detection of Obstructive Coronary Artery Disease (Moderated Posters 8, Science and Technology Hall) -  Aug 21, 2019 - Abstract #AHA2019AHA_7075;    
    Sensitivity, specificity, + and - predictive values (PPV and NPV, respectively) of ARM are equivalent to RMPI for detection of severe obstructive (≥ 70%) left main or 3-vessel (3VD) or ≥ 70% CAD in any artery or graft (ANY) by CTA or ICA in veterans referred for cardiac stress testing. Thus, ARM may be a viable and cost-effective alternative in patients unable to perform leg exercise.
  • ||||||||||  hydralazine hydrochloride / Generic Mfg., Lexiscan (regadenoson) / Astellas
    Aortic Stiffness is Associated With a Reduced Coronary Flow Reserve (Zone 4, Science and Technology Hall) -  Aug 21, 2019 - Abstract #AHA2019AHA_3282;    
    We assessed the relationship between coronary flow reserve and carotid-femoral pulse wave velocity (CF-PWV) among 101 patients referred for a clinically indicated regadenoson stress cardiac MRI study. Consistent with its important hemodynamic effect on coronary perfusion pressure, our study demonstrated that increased large artery stiffness is associated with a reduced myocardial perfusion reserve.
  • ||||||||||  Lexiscan / Astellas
    Clinical, Journal:  Feasibility, safety and effectiveness in measuring microvascular resistance with regadenoson invasive coronary flow assessment with regadenoson. (Pubmed Central) -  Aug 11, 2019   
    There was a significant drop in transit mean time from baseline to hyperemia of more than 50% (1.0 ± 0.6 s vs. 0.4 ± 0.2 s, p <  0.01). Patients' mean IMR value was 23.4, and IMR values above 75th percentile significantly correlated with metformin demanding diabetes mellitus with OR 21.76 and nicotine abuse with OR 10.28.CONCLUSIONA single intravenous regadenoson bolus via peripheral line increases coronary blood flow without harmful systemic side effects enabling interventionists to simultaneously assess FFR, CFR and IMR in patients with stable coronary artery disease.
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion date, Trial primary completion date:  Quantitative 13N-Ammonia Cardiac Rest/Stress Digital PET/CT (clinicaltrials.gov) -  Jul 17, 2019   
    P=N/A,  N=30, Recruiting, 
    Patients' mean IMR value was 23.4, and IMR values above 75th percentile significantly correlated with metformin demanding diabetes mellitus with OR 21.76 and nicotine abuse with OR 10.28.CONCLUSIONA single intravenous regadenoson bolus via peripheral line increases coronary blood flow without harmful systemic side effects enabling interventionists to simultaneously assess FFR, CFR and IMR in patients with stable coronary artery disease. Trial completion date: Mar 2019 --> Mar 2020 | Trial primary completion date: Mar 2019 --> Mar 2020
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion date, Trial primary completion date:  Microvascular Blood Flow in Sickle Cell Anemia (clinicaltrials.gov) -  Jul 10, 2019   
    P=N/A,  N=200, Active, not recruiting, 
    Trial completion date: Mar 2019 --> Mar 2020 | Trial primary completion date: Mar 2019 --> Mar 2020 Trial completion date: Dec 2019 --> Jan 2022 | Trial primary completion date: Dec 2017 --> Jan 2022
  • ||||||||||  Lexiscan (regadenoson) / GE Healthcare, Astellas, Gilead
    Trial completion date, Trial primary completion date:  Allograft Dysfunction in Heart Transplant (clinicaltrials.gov) -  Jul 9, 2019   
    P4,  N=36, Recruiting, 
    Trial completion date: Dec 2019 --> Jan 2022 | Trial primary completion date: Dec 2017 --> Jan 2022 Trial completion date: Apr 2019 --> Apr 2020 | Trial primary completion date: Apr 2019 --> Apr 2020